Fda awards $2.6 million grant for expanded study of soligenix's hybryte(tm) for ctcl

New york, new york--(newsfile corp. - september 12, 2022) - pcg digital -- late-stage biopharmaceutical company soligenix, inc. (nasdaq: sngx) has announced the award of a $2.6 million grant from the fda to support a study of expanded hybryte™ treatment, including at-home usage. the fda's support will give patients an opportunity to access soligenix's hybryte™ therapy in an open-label setting.
SNGX Ratings Summary
SNGX Quant Ranking